Overview

About this study

The main objective of this protocol is to allow us to use human peripheral blood samples from Caribbean patients, collected at Mayo Clinic under the approved IRB Number: 16-008485. Additional blood samples from patients consented under this IRB will also be used for this purpose. We will use these samples to isolate immune cells and perform single cell RNA sequencing. We hypothesize that the data obtained from this study will be instrumental in identifying RNA profiles specific to Latin American populations, providing vital information for the development of truly global therapeutic strategies that take into account diverse populations.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Individuals whose place of origin is in the Caribbean countries.

Exclusion Criteria: 

  • <  than 18 years old.
  • Having an active fever.
  • Being diagnosed with/suspecting to have an infectious condition (such as influenza, COVID-19, etc), and/or being diagnosed with any chronic immunodeficiency disorder.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Hugo Guerrero Cazares, M.D., Ph.D.

Open for enrollment

Contact information:

Aleeshba Basil

(904) 953-3703

Basil.Aleeshba@mayo.edu

More information

Publications

Publications are currently not available